北陆药业 (300016)

Beijing Beilu Pharmaceutical Co.,Ltd

ASZ

Tags

Specialized-Sophisticated-Distinctive-Innovative EnterprisesArtificial Intelligence (AI)Brain-Computer InterfaceVenture Capital ConceptInnovative DrugsPharmaceutical ManufacturingInvestments in Financial InstitutionsGene ConceptPrivate Placement ProposalsSmart Healthcare

K-Line Chart

No K-line data

Stock Details

1. Key Indicators

  • Total Shares(W): 56287.32
  • Circulating A-Shares(W): 56211.47
  • Earnings Per Share(RMB): 0.0870
  • Net Assets Per Share(RMB): 3.9282
  • Operating Revenue(W RMB): 87268.50
  • Total Profit(W RMB): 4498.46
  • Net Profit Attributable to Parent(W RMB): 4417.69
  • Net Profit Growth Rate(%): 81.10
  • Weighted Return on Equity(%): 2.4600
  • Operating Cash Flow Per Share(RMB): 0.2300
  • Undistributed Profit Per Share(RMB): 1.4082
  • Capital Reserve Per Share(RMB): 1.2399

2. Main Business

The main business covers:

  • Production and sales of contrast agents
  • Production and sales of hypoglycemic drugs
  • Production and sales of central nervous system traditional Chinese medicines

3. Company Basic Information

  • Company Name: Beijing Beilu Pharmaceutical Co., Ltd.
  • Listing Date: 2009-10-30
  • Industry: Pharmaceutical Manufacturing
  • Address: 7th Floor, Block A, Fenglan International Office Building, No. 32 Xizhimen North Street, Haidian District, Beijing
  • Website: www.beilu.com.cn
  • Company Profile: Beijing Beilu Pharmaceutical Co., Ltd. was formerly known as Beijing Beilu Pharmaceutical and Chemical Company. In August 1992, Wang Daixue, as the actual investor, invested 300,000 yuan to establish Beijing Beilu Pharmaceutical and Chemical Company. In August 1993, Wang Daixue became the general manager. In May 1996, Beijing Beilu Pharmaceutical and Chemical Company underwent a share cooperative system reform. The shareholding reform working group decided to allocate part of the share capital to employees based on their contributions, positions, and seniority. The original investor, Wang Daixue, transferred 26.48% of the share capital from the net assets to other natural person shareholders. After asset appraisal, the net assets of Beijing Beilu Pharmaceutical and Chemical Company were 1,946,511.29 yuan, the state support fund was 276,871.89 yuan, the employee insurance fund was 68,260.00 yuan, and the share capital was 1,601,379.40 yuan, all of which were held by individual employees. Among them, investor Wang Daixue contributed 1,177,334.15 yuan, accounting for 73.52% of the total share capital, 9 employees with outstanding contributions accounted for 22%, and the other 28 employees accounted for 4.48%. After the share cooperative system reform, the company's name was changed to Beijing Beilu Pharmaceutical and Chemical Group, and the registered capital was increased to 1.6 million yuan. In July 1999, Beijing Beilu Pharmaceutical and Chemical Group conducted an internal equity transfer. After integration, investor Wang Daixue held 80% of the equity of Beijing Beilu Pharmaceutical and Chemical Group, Hong Wei held 10%, and Yao Zhenping held 10%. In August 1999, Beijing Venture Capital Co., Ltd. jointly initiated the establishment of Beijing Beilu Pharmaceutical Co., Ltd. with the natural person shareholders of Beijing Beilu Pharmaceutical and Chemical Group, Wang Daixue, Hong Wei, and Yao Zhenping. The company's equity structure was: Wang Daixue contributed 14.1 million yuan, accounting for 40% of the equity, of which 10.2926 million yuan was net asset investment and 3.8074 million yuan was monetary investment. Beijing Venture Capital Co., Ltd. contributed 14.1 million yuan in cash, accounting for 40% of the equity. Hong Wei contributed 3.525 million yuan, accounting for 10% of the equity, of which 2.5732 million yuan was net asset investment and 951,800 yuan was monetary investment. Yao Zhenping contributed 3.525 million yuan, accounting for 10% of the equity, of which 2.5732 million yuan was net asset investment and 951,800 yuan was monetary investment. In September 1999, it was approved by the Beijing Administration for Industry and Commerce and changed to a limited liability company.

4. Top 10 Circulating Shareholders

Rank Institution Name Institution Type Shares Held (W) Percentage Held (%)
1 Chongqing Sanxia Paint Co., Ltd. General Legal Person 3746.57 6.67
2 China Resources Yukang Asset Management Co., Ltd. General Legal Person 1500.00 2.67
3 Guolian Medical and Health Selected Hybrid Securities Investment Fund Class A Fund 19.03 0.03

5. Concept Sectors

  • Venture Capital Concept
  • Gene Concept
  • Intelligent Healthcare
  • Artificial Intelligence
  • Brain-Computer Interface
  • Innovative Drugs
  • Financial Holdings
  • Private Placement Plan
  • Specialized, Refined, Distinctive, and Innovative Enterprises

Remarks

  • Data update date: 2026-01-01
  • Data source: Public Market Information